| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600200 from our risk checks.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.96 |
| 52 Week High | CN¥13.88 |
| 52 Week Low | CN¥6.90 |
| Beta | 0.19 |
| 1 Month Change | -13.15% |
| 3 Month Change | 36.15% |
| 1 Year Change | 30.94% |
| 3 Year Change | 44.59% |
| 5 Year Change | 78.50% |
| Change since IPO | 95.72% |
Recent News & Updates
Shareholder Returns
| 600200 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.8% | 5.6% | 3.1% |
| 1Y | 30.9% | -11.0% | -13.1% |
Return vs Industry: 600200 exceeded the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 600200 exceeded the CN Market which returned -13.1% over the past year.
Price Volatility
| 600200 volatility | |
|---|---|
| 600200 Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 600200's share price has been volatile over the past 3 months.
Volatility Over Time: 600200's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,050 | Qunshan Qian | www.600200.com |
JiangSu WuZhong Pharmaceutical Development Co., Ltd. engages in pharmaceutical, medical cosmetology, investment, and other industries in China and internationally. It provides genetic and chemical drugs in the fields of anti-virus, anti infection, immune regulation, anti-tumor, digestive system, cardiovascular, etc.; and modern traditional Chinese medicine.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Fundamentals Summary
| 600200 fundamental statistics | |
|---|---|
| Market cap | CN¥7.72b |
| Earnings (TTM) | -CN¥95.04m |
| Revenue (TTM) | CN¥2.33b |
3.3x
P/S Ratio-81.2x
P/E RatioIs 600200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600200 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.33b |
| Cost of Revenue | CN¥1.79b |
| Gross Profit | CN¥536.77m |
| Other Expenses | CN¥631.81m |
| Earnings | -CN¥95.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 23.02% |
| Net Profit Margin | -4.08% |
| Debt/Equity Ratio | 101.1% |
How did 600200 perform over the long term?
See historical performance and comparison